Nicholas J. Laping - Concepedia

Author

Nicholas J. Laping

Also Known As

N J Laping, N LAPING, N Laping, N. J. Laping, N. Laping, N.J Laping, N.J. Laping, NICHOLAS J. LAPING, Nicholas J Laping, Nicholas J. Laping

101

Publications

Citations

H-Index

118

Concepts

All Affiliations

GlaxoSmithKline (United States)University of Southern California New Frontier GlaxoSmithKline (United Kingdom)Research Triangle Park Foundation

About

Nicholas J. Laping is an author at GlaxoSmithKline (United States) specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	43	3K
2	Social Sciences	10	10	533
3	Health Sciences	5	5	121
4	Natural Sciences	3	3	161
5	Public Health	2	2	185

Nicholas J. Laping

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7 Gareth J. Inman, Francisco José Nicolás, James F. Callahan, Molecular Pharmacology	2002	1.6K
Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542 Nicholas J. Laping, Eugene T. Grygielko, Anil Mathur, Molecular Pharmacology	2002	647
GFAP mRNA increases with age in rat and human brain Nancy R. Nichols, Jonathan Day, Nicholas J. Laping, Neurobiology of Aging Neurodegenerative DiseasesAlzheimer's DiseaseAgingLongevityPhysiology	1993	414
SB-505124 Is a Selective Inhibitor of Transforming Growth Factor-β Type I Receptors ALK4, ALK5, and ALK7 Stacey DaCosta Byfield, Christopher Major, Nicholas J. Laping, Molecular Pharmacology	2004	412
N-((1 S)-1-{[4-((2 S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part I Kevin S. Thorneloe, Anthony C. Sulpizio, Zuojun Lin, Journal of Pharmacology and Experimental Therapeutics	2008	400
Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5) James F. Callahan, Joelle L. Burgess, James A. Fornwald, Journal of Medicinal Chemistry Drug TargetPharmacotherapyCell GrowthTumor BiologyGrowth Factor Beta1	2002	309
Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis Maj Petersen, Midory Thorikay, Martijn Deckers, Kidney International InflammationFibrosisUrologyKidney ResearchMedicine	2007	213
Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer Therapeutic Andrea B. Sherk, Daniel E. Frigo, Christine G. Schnackenberg, Cancer Research	2008	207
AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome Erin S. R. Lashinger, Matthew S. Steiginga, J. Paul Hieble, American Journal of Physiology-Renal Physiology	2008	204
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee, PubMed Molecular PharmacologyNeuro-oncologyAngiogenesisGliomaMedicine	2004	192

Page 1